{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:12:37Z","timestamp":1790266357506,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key project of the National Natural Science Foundation of China","award":["none"],"award-info":[{"award-number":["none"]}]},{"name":"Research Foundation of Education Bureau of Guangdong Province, China","award":["Grant cxzd1103"],"award-info":[{"award-number":["Grant cxzd1103"]}]},{"name":"Natural Science Foundation of Guangdong province","award":["Grant 2015A030312014"],"award-info":[{"award-number":["Grant 2015A030312014"]}]},{"name":"National Natural Science Foundation of China Youth Foud","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["Grant 2019M653237"],"award-info":[{"award-number":["Grant 2019M653237"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uveal melanoma (UM) is the most common primary intraocular tumor. Hepatic metastasis is the major and direct death-related reason in UM patients. Given that cancer stem-like cells (CSCs) are roots of metastasis, targeting CSCs may be a promising strategy to overcome hepatic metastasis in UM. Salinomycin, which has been identified as a selective inhibitor of CSCs in multiple types of cancer, may be an attractive agent against CSCs thereby restrain hepatic metastasis in UM. The objective of the study is to explore the antitumor activity of salinomycin against UM and clarify its underlying mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>UM cells were treated with salinomycin, and its effects on cell proliferation, apoptosis, migration, invasion, CSCs population, and the related signal transduction pathways were determined. The in vivo antitumor activity of salinomycin was evaluated in the NOD\/SCID UM xenograft model and intrasplenic transplantation liver metastasis mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that salinomycin remarkably obviated growth and survival in UM cell lines and in a UM xenograft mouse model. Meanwhile, salinomycin significantly eliminated CSCs and efficiently hampered hepatic metastasis in UM liver metastasis mouse model. Mechanistically, Twist1 was fundamental for the salinomycin-enabled CSCs elimination and migration\/invasion blockage in UM cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that targeting UM CSCs by salinomycin is a promising therapeutic strategy to hamper hepatic metastasis in UM. These results provide the first pre-clinical evidence for further testing of salinomycin for its antitumor efficacy in UM patients with hepatic metastasis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-019-1068-1","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T05:13:36Z","timestamp":1573622016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Jingfeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/CCO.0000000000000425","volume":"30","author":"V Chua","year":"2018","unstructured":"Chua V, Aplin AE. Novel therapeutic strategies and targets in advanced uveal melanoma. Curr Opin Oncol. 2018;30:134\u201341.","journal-title":"Curr Opin Oncol"},{"key":"1068_CR2","doi-asserted-by":"crossref","first-page":"175883401875717","DOI":"10.1177\/1758834018757175","volume":"10","author":"J Yang","year":"2018","unstructured":"Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018757175.","journal-title":"Ther Adv Med Oncol"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/ICU.0000000000000051","volume":"25","author":"MG Field","year":"2014","unstructured":"Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25:234\u20139.","journal-title":"Curr Opin Ophthalmol"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/aos.13580","volume":"96","author":"M Dogrusoz","year":"2018","unstructured":"Dogrusoz M, Jager MJ. Genetic prognostication in uveal melanoma. Acta Ophthalmol. 2018;96:331\u201347.","journal-title":"Acta Ophthalmol"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","volume":"148","author":"JJ Augsburger","year":"2009","unstructured":"Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119\u201327.","journal-title":"Am J Ophthalmol"},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","volume":"457","author":"CD Van Raamsdonk","year":"2009","unstructured":"Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599\u2013602.","journal-title":"Nature."},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","volume":"25","author":"X Feng","year":"2014","unstructured":"Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831\u201345.","journal-title":"Cancer Cell"},{"key":"1068_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38\u201344.","journal-title":"Br J Ophthalmol"},{"key":"1068_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/PPO.0b013e31824bd256","volume":"18","author":"SE Woodman","year":"2012","unstructured":"Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012;18:148\u201352.","journal-title":"Cancer J"},{"key":"1068_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/1535-7163.MCT-16-0552","volume":"16","author":"H Cheng","year":"2017","unstructured":"Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, et al. Co-targeting HGF\/cMET signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 2017;16:516\u201328.","journal-title":"Mol Cancer Ther"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massague","year":"2016","unstructured":"Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298\u2013306.","journal-title":"Nature."},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.stem.2014.02.002","volume":"14","author":"T Oskarsson","year":"2014","unstructured":"Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14:306\u201321.","journal-title":"Cell Stem Cell"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell."},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/0008-5472.CAN-14-3225","volume":"75","author":"V Adorno-Cruz","year":"2015","unstructured":"Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75:924\u20139.","journal-title":"Cancer Res"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2017.03.008","volume":"396","author":"Y Li","year":"2017","unstructured":"Li Y, Atkinson K, Zhang T. Combination of chemotherapy and cancer stem cell targeting agents: preclinical and clinical studies. Cancer Lett. 2017;396:103\u20139.","journal-title":"Cancer Lett"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/sci.2017.10.04","volume":"4","author":"M Nawaz","year":"2017","unstructured":"Nawaz M. Extracellular vesicle-mediated transport of non-coding RNAs between stem cells and cancer cells: implications in tumor progression and therapeutic resistance. Stem Cell Investig. 2017;4:83.","journal-title":"Stem Cell Investig"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645\u201359.","journal-title":"Cell."},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1038\/onc.2016.59","volume":"35","author":"AK Najumudeen","year":"2016","unstructured":"Najumudeen AK, Jaiswal A, Lectez B, Oetken-Lindholm C, Guzman C, Siljamaki E, et al. Cancer stem cell drugs target K-ras signaling in a stemness context. Oncogene. 2016;35:5248\u201362.","journal-title":"Oncogene."},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3892\/or.2015.4253","volume":"34","author":"C Zhang","year":"2015","unstructured":"Zhang C, Tian Y, Song F, Fu C, Han B, Wang Y. Salinomycin inhibits the growth of colorectal carcinoma by targeting tumor stem cells. Oncol Rep. 2015;34:2469\u201376.","journal-title":"Oncol Rep"},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.07.016","volume":"311","author":"QL Tang","year":"2011","unstructured":"Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311:113\u201321.","journal-title":"Cancer Lett"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"950658","DOI":"10.1155\/2012\/950658","volume":"2012","author":"C Naujokat","year":"2012","unstructured":"Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.","journal-title":"J Biomed Biotechnol"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"13253","DOI":"10.1073\/pnas.1110431108","volume":"108","author":"D Lu","year":"2011","unstructured":"Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108:13253\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cbi.2018.09.018","volume":"296","author":"L Liu","year":"2018","unstructured":"Liu L, Wang Q, Mao J, Qin T, Sun Y, Yang J, et al. Salinomycin suppresses cancer cell stemness and attenuates TGF-beta-induced epithelial-mesenchymal transition of renal cell carcinoma cells. Chem Biol Interact. 2018;296:145\u201353.","journal-title":"Chem Biol Interact"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3802\/jgo.2017.28.e14","volume":"28","author":"HG Lee","year":"2017","unstructured":"Lee HG, Shin SJ, Chung HW, Kwon SH, Cha SD, Lee JE, et al. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell. J Gynecol Oncol. 2017;28:e14.","journal-title":"J Gynecol Oncol"},{"key":"1068_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/nchem.2778","volume":"9","author":"TT Mai","year":"2017","unstructured":"Mai TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 2017;9:1025\u201333.","journal-title":"Nat Chem"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1080\/15548627.2017.1327104","volume":"13","author":"A Hamai","year":"2017","unstructured":"Hamai A, Caneque T, Muller S, Mai TT, Hienzsch A, Ginestier C, et al. An iron hand over cancer stem cells. Autophagy. 2017;13:1465\u20136.","journal-title":"Autophagy."},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1158\/1078-0432.CCR-17-1703","volume":"24","author":"Y Jin","year":"2018","unstructured":"Jin Y, Zhang P, Wang Y, Jin B, Zhou J, Zhang J, et al. Neddylation blockade diminishes hepatic metastasis by dampening Cancer stem-like cells and angiogenesis in uveal melanoma. Clin Cancer Res. 2018;24:3741\u201354.","journal-title":"Clin Cancer Res"},{"key":"1068_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.7150\/thno.17451","volume":"7","author":"J Zhou","year":"2017","unstructured":"Zhou J, Jin B, Jin Y, Liu Y, Pan J. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics. 2017;7:1447\u201362.","journal-title":"Theranostics."},{"key":"1068_CR29","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1172\/JCI85239","volume":"126","author":"Y Jin","year":"2016","unstructured":"Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 2016;126:3961\u201380.","journal-title":"J Clin Invest"},{"key":"1068_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1158\/1078-0432.CCR-17-1533","volume":"24","author":"J Zhou","year":"2018","unstructured":"Zhou J, Nie D, Li J, Du X, Lu Y, Li Y, et al. PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia. Clin Cancer Res. 2018;24:145\u201357.","journal-title":"Clin Cancer Res"},{"key":"1068_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","volume":"117","author":"J Yang","year":"2004","unstructured":"Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927\u201339.","journal-title":"Cell."},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/leu.2011.199","volume":"26","author":"DJ Morrison","year":"2012","unstructured":"Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012;26:271\u20139.","journal-title":"Leukemia."},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"W Dai","year":"2016","unstructured":"Dai W, Zhou J, Jin B, Pan J. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016;6:1\u201314.","journal-title":"Sci Rep"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41467-017-00396-9","volume":"8","author":"X Tang","year":"2017","unstructured":"Tang X, Shi L, Xie N, Liu Z, Qian M, Meng F, et al. SIRT7 antagonizes TGF-beta signaling and inhibits breast cancer metastasis. Nat Commun. 2017;8:318.","journal-title":"Nat Commun"},{"key":"1068_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.exer.2005.11.024","volume":"83","author":"H Li","year":"2006","unstructured":"Li H, Niederkorn JY, Neelam S, Alizadeh H. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res. 2006;83:176\u201382.","journal-title":"Exp Eye Res"},{"key":"1068_CR36","first-page":"919","volume":"21","author":"L Asnaghi","year":"2015","unstructured":"Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, et al. EMT-associated factors promote invasive properties of uveal melanoma cells. Mol Vis. 2015;21:919\u201329.","journal-title":"Mol Vis"},{"key":"1068_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2014.12.037","volume":"358","author":"M Schenk","year":"2015","unstructured":"Schenk M, Aykut B, Teske C, Giese NA, Weitz J, Welsch T. Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Cancer Lett. 2015;358:161\u20139.","journal-title":"Cancer Lett"},{"key":"1068_CR38","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1016\/j.bbagen.2013.01.010","volume":"1830","author":"Y Al Dhaheri","year":"2013","unstructured":"Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Eid A, Al Faresi N, et al. Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta. 2013;1830:3121\u201335.","journal-title":"Biochim Biophys Acta"},{"key":"1068_CR39","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1038\/cddis.2013.223","volume":"4","author":"KH Koo","year":"2013","unstructured":"Koo KH, Kim H, Bae YK, Kim K, Park BK, Lee CH, et al. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis. 2013;4:e693.","journal-title":"Cell Death Dis"},{"key":"1068_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/ncb1010-924","volume":"12","author":"A Martin","year":"2010","unstructured":"Martin A, Cano A. Tumorigenesis: Twist1 links EMT to self-renewal. Nat Cell Biol. 2010;12:924.","journal-title":"Nat Cell Biol"},{"key":"1068_CR41","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.7150\/thno.21477","volume":"8","author":"J Cao","year":"2018","unstructured":"Cao J, Wang X, Dai T, Wu Y, Zhang M, Cao R, et al. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. Theranostics. 2018;8:2739\u201351.","journal-title":"Theranostics."},{"key":"1068_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature13305","volume":"511","author":"S Boumahdi","year":"2014","unstructured":"Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511:246.","journal-title":"Nature."},{"key":"1068_CR43","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/onc.2011.338","volume":"31","author":"O Leis","year":"2012","unstructured":"Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi M, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354.","journal-title":"Oncogene."},{"key":"1068_CR44","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1038\/oncsis.2013.23","volume":"2","author":"M Herreros-Villanueva","year":"2013","unstructured":"Herreros-Villanueva M, Zhang J, Koenig A, Abel E, Smyrk TC, Bamlet W, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013;2:e61.","journal-title":"Oncogenesis."}],"updated-by":[{"DOI":"10.1186\/s12943-021-01334-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-1068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-019-1068-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-1068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T10:06:43Z","timestamp":1614766003000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-019-1068-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/s12943-019-1068-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-021-01334-6","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-021-01334-6","URL":"https:\/\/doi.org\/10.1186\/s12943-021-01334-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal studies were approved by the Sun Yat-sen University Institutional Animal Care and Use Committee as described in Methods section.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}